SCHEMBL24924339

SCHEMBL24924339

CC(C)c1ccc(-c2cc(=O)n(C)cn2)cc1O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.40
LMNA P02545 1/20 0.40
CHRM1 P11229 1/20 0.40
SLC6A2 P23975 1/20 0.40
ADRA1A P35348 1/20 0.40
HTR2B P41595 1/20 0.40
HSD11B1 P28845 1/20 0.35
EP300 Q09472 1/20 0.35
SYK P43405 8/20 0.34
TRPV1 Q8NER1 1/20 0.34
KDM2B Q8NHM5 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRB2 P47870 1/20 0.33
HSP90AA1 P07900 2/20 0.32
ESRRG P62508 1/20 0.32
HSP90AB1 P08238 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22214073 0.81 TRPA1 (0.43) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL25092457 0.76 TRPA1 (0.39) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL24924345 0.75 BRD4 (0.47) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL16528005 0.72 LMNA (0.64) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL22214097 0.71 ERCC1 (0.40) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL22214038 0.71 TRPA1 (0.40) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL22313780 0.71 HTT (0.34) SLC6A2EP300SYKKDM2BKDM4C
SCHEMBL10842926 0.70 ALDH1A1 (0.46)
SCHEMBL31010850 0.70 NPC1 (0.51) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL22214098 0.69 PIK3CD (0.45) TRPA1LMNACHRM1SLC6A2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 TRPA1 4510/4885LMNA 218/4885CHRM1 4689/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 TRPA1 4516/4885LMNA 246/4885CHRM1 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.